Journal of Clinical and Aesthetic Dermatology

Psoriasis and Cutaneous Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 28 of 35

Dermatol. 2014;53(6):714–722. 9. Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013;24(5):356–360. 10. Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3): 333–337. 11. Strober B, Zhao Y, Tran MH, et al. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. Int J Dermatol. 2016;55(3):e147–e155. 12. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115. 13. Cather J, Horn E, Sundaram M, Bao Y. Sex-specific differences in health-related quality of life in patients with moderate to severe psoriasis. American Academy of Dermatology; 2012. 14. Kimball A, Sundaram M, Mulani P, Bao Y. Quality of life effects on psoriasis skin symptoms affecting different body regions. American Academy of Dermatology; 2012. Poster 4795. 15. Martin ML, McCarrier KP, Chiou CF, et al. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient- reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. Aug 2013;24(4):255–260. 16. Feldman S, Bushnell DM, Kircik L, et al. Differences in patient reported psoriasis symptom severity between patients rated as "clear" versus "almost clear" based on Physician Global Assessment. American Academy of Dermatology; 2015. 17. Soung J, Chapman S, Langley RG, et al. Psoriasis efficacy of apremilast or etanercept compared with placebo in patients with moderate to severe psoriasis: Results from the LIBERATE study. EADV 20152015. 18. Reich K, Thaci D, Ghislain P-D, et al. Analysis of psoriasis area and severity index and weight change during long term treatment with apremilast in patients with moderate to severe plaque psoriasis (ESTEEM 1). American Academy of Dermatology; 2015. 19. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–677. 20. Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non- inferiority trial. Lancet. 2015;386(9993):552–561. 21. Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol. 2016;152(4):492–493. 22. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–399. 23. Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110–1112. 24. Ortonne JP, Tasset C, Reich K, Sterry W. Safety and efcacy of subcutaneous certolizumab pegol, a new anti-TNFα monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: preliminary results from a double- blind, placebo-controlled trial. J Am Acad Dermatol. 2007;56[Suppl 2], AB6. 25. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461–467. 26. Gordon KB, Duffin KC, Bissonnette R, et al. A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. New Eng J Med. 2015;373(2):136–144. 27. Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a Phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–939. 28. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo- controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124; e117. 29. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. New Eng J Med. 2014;371(4):326–338. 30. Oussova T. Cosentyx (secukinumab) for injection, for subcutaneous use for the treatment of moderate to severe plaque psoriasis. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting 2014. downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/DermatologicandOphthalmicDrugsAdvisor yCommittee/UCM420461.pdf. Accessed on May 25, 2015. 31. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to- severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. 32. Schmidt CG. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug. Nat Biotechnol. 2015;33(9): 894–895. 33. Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411. 34. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659. 35. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268–269. 36. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis U pdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting [ S E P T E M B E R 2 0 1 6 • V O L U M E 9 • N U M B E R 9 ] S U P P L E M E N T T O T H E J O U R N A L O F C L I N I C A L A N D A E S T H E T I C D E R M AT O L O G Y S 2 5

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Psoriasis and Cutaneous Supplement 2016